The giant swiss pharmaceutical Novartis announced that it was terminating the clinical trial with hydroxychloroquine to treat patients of the Covid-19 due to lack of participants.
on April 20, The group announced it had entered into an agreement with the u.s. agency of medicines, the Food and drug administration (FDA) to conduct phase III clinical trials of hydroxychloroquine in patients of the Covid-19 hospitalized.
